ZAGBEMIZ Trademark

Trademark Overview


On Wednesday, January 3, 2024, a trademark application was filed for ZAGBEMIZ with the United States Patent and Trademark Office. The USPTO has given the ZAGBEMIZ trademark a serial number of 98339914. The federal status of this trademark filing is REGISTERED as of Tuesday, January 14, 2025. This trademark is owned by Staidson (Beijing) Biopharmaceuticals Co., Ltd.. The ZAGBEMIZ trademark is filed in the Pharmaceutical Products category with the following description:

Medicines for human purposes, namely, medicines for the treatment of cancer, cardiovascular diseases, hematologic diseases, neurological diseases, gastrointestinal and genetic diseases, inflammatory diseases, autoimmune diseases, infectious diseases, coagulation disorders, infectious and parasitic diseases, neoplasms, diseases of the blood and blood-forming organs, endocrine, nutritional and metabolic diseases, mental, behavioral and neurodevelopmental disorders, sleep-wake disorders, diseases of the nervous system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin, congenital bleeding disorders and acquired bleeding disorders, disorders due to a deficiency of a coagulation factor, disorders due to the presence of acquired inhibitors to a coagulation factor, hematologic disorders, hemorrhagic disorders, Von Willebrands' disease, disorders resulting from anticoagulant therapy with a vitamin-K antagonist, hereditary platelet disorders, vitamin K e...
zagbemiz

General Information


Serial Number98339914
Word MarkZAGBEMIZ
Filing DateWednesday, January 3, 2024
Status700 - REGISTERED
Status DateTuesday, January 14, 2025
Registration Number7649392
Registration DateTuesday, January 14, 2025
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 17, 2024

Trademark Statements


Goods and ServicesMedicines for human purposes, namely, medicines for the treatment of cancer, cardiovascular diseases, hematologic diseases, neurological diseases, gastrointestinal and genetic diseases, inflammatory diseases, autoimmune diseases, infectious diseases, coagulation disorders, infectious and parasitic diseases, neoplasms, diseases of the blood and blood-forming organs, endocrine, nutritional and metabolic diseases, mental, behavioral and neurodevelopmental disorders, sleep-wake disorders, diseases of the nervous system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin, congenital bleeding disorders and acquired bleeding disorders, disorders due to a deficiency of a coagulation factor, disorders due to the presence of acquired inhibitors to a coagulation factor, hematologic disorders, hemorrhagic disorders, Von Willebrands' disease, disorders resulting from anticoagulant therapy with a vitamin-K antagonist, hereditary platelet disorders, vitamin K epoxide reductase C1 deficiency, gamma-carboxylase deficiency, bleeding associated with trauma, injury, and surgery, thrombosis, thrombocytopenia, stroke, coagulopathy, disseminated intravascular coagulation (DIC), Bernard Soulier syndrome, Glanzman thromblastemia, storage pool deficiency, and hemophilia; pharmaceutical preparations and substances for the treatment of viral diseases, metabolic diseases, endocrine diseases, musculoskeletal diseases, cardiovascular diseases, hematologic diseases, cardiopulmonary diseases, genitourinary diseases, sexual dysfunction, oncological diseases, hepatological diseases, ophthalmic diseases, respiratory diseases, neurological diseases, gastrointestinal diseases, hormonal diseases, dermatological diseases, coagulation disorders, diseases of the blood and blood-forming organs, psychiatric and immune system related diseases and disorders, congenital bleeding disorders and acquired bleeding disorders, disorders due to a deficiency of a coagulation factor, disorders due to the presence of acquired inhibitors to a coagulation factor, hematologic disorders, hemorrhagic disorders, Von Willebrands' disease, disorders resulting from anticoagulant therapy with a vitamin-K antagonist, hereditary platelet disorders, vitamin K epoxide reductase C1 deficiency, gamma-carboxylase deficiency, bleeding associated with trauma, injury, and surgery, thrombosis, thrombocytopenia, stroke, coagulopathy, disseminated intravascular coagulation (DIC), Bernard Soulier syndrome, Glanzman thromblastemia, storage pool deficiency, and hemophilia; diagnostic preparations for medical purposes; dietetic foods and beverages adapted for medical use; depuratives for the body; veterinary pharmaceutical compounds for equine use to treat conditions of the leg, hoof, ear, nose and throat; pesticides; first aid kits; dental abrasives.

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, January 3, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameJIANGSU BIOJETAY BIOTECHNOLOGY CO., LTD.
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressWUXI CITY 214000
CN

Party NameJIANGSU BIOJETAY BIOTECHNOLOGY CO., LTD.
Party Type21 - New Owner After Publication
Legal Entity Type99 - Other
AddressWUXI CITY 214000
CN

Party NameStaidson (Beijing) Biopharmaceuticals Co., Ltd.
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressBeijing
CN

Party NameStaidson (Beijing) Biopharmaceuticals Co., Ltd.
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressBeijing
CN

Trademark Events


Event DateEvent Description
Thursday, April 18, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, January 3, 2024NEW APPLICATION ENTERED
Tuesday, July 30, 2024ASSIGNED TO EXAMINER
Friday, August 9, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, August 28, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, September 17, 2024PUBLISHED FOR OPPOSITION
Tuesday, September 17, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, December 11, 2024AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Tuesday, January 14, 2025REGISTERED-PRINCIPAL REGISTER
Tuesday, January 14, 2025NOTICE OF REGISTRATION CONFIRMATION EMAILED
Thursday, January 23, 2025TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, January 23, 2025ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, January 23, 2025TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Thursday, January 23, 2025TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
Thursday, January 23, 2025TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED